A phase II study of an oxaliplatin/vinorelbine/5-fluorouracil combination in patients with anthracycline-pretreated and taxane-pretreated metastatic breast cancer

Anti-Cancer Drugs

Volumn 17, Issue 9, 2006, Pages 1067-1073

  Delozier, Thierry ^a   Guastalla, Jean Paul ^b   Yovine, Alejandro ^c,j   Levy, Christelle ^a   Chollet, Philippe ^d   Mousseau, Mireille ^e   Delva, Rémy ^f   Coeffic, David ^g   Vannetzel, Jean Michel ^h   Zazzi, Eliette Sudriez ⁱ   Brienza, Silvano ⁱ   Cvitkovic, Esteban ^c  

^a CENTRE FRANÇOIS BACLESSE   (France)

^b CENTRE LÉON BÉRARD   (France)

^c Cvitkovic et Associes Consultants   (France)

^d CENTRE JEAN PERRIN   (France)

^e GRENOBLE UNIVERSITY HOSPITAL   (France)

^f CENTRE PAUL PAPIN   (France)

^g Institut Privé de Cancérologie IPC   (France)

^h Clinique Hartmann   (France)

ⁱ Debioclinic ^*  (France)

^j CAC   (France)

more..

Author keywords

5 fluorouracil; Breast cancer; Oxaliplatin; Vinorelbine

Indexed keywords

ANTHRACYCLINE; FLUOROURACIL; NAVELBINE; OXALIPLATIN; TAXANE DERIVATIVE;

ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANXIETY; ARTICLE; ASTHENIA; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DYSESTHESIA; DYSPNEA; ERYTHROCYTE TRANSFUSION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; LEUKOPENIA; LIVER METASTASIS; LUNG CARCINOMA; LUNG EMBOLISM; LYMPHANGITIS; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PAIN; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; STOMATITIS; THORAX PAIN; THROMBOCYTOPENIA;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; TAXOIDS; VINBLASTINE;

EID: 33749032787     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000231475.77159.aa     Document Type: Article

References (43)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55:10-30.
2. Insa A, Lluch A, Prosper F, Marugan I, Martinez-Agullo A, Garcia-Conde J. Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients. Breast Cancer Res Treat 1999; 56:67-78.
3. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005; 352:2302-2313.
4. Nabholtz JM, Falkson C, Campos D, Szanto J, Martin M, Chan S, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, Phase III trial. J Clin Oncol 2003; 21:968-975.
5. Livingston R, Ellis G, Gralow J, Williams MA, White R, McGuirt C, et al. Dose-intensive vinorelbine with current granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1997; 15:1395-1400.
6. Fumoleau P, Largiller R, Clippe C, Dieras V, Orfeuvre H, Lesimple T, et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated meastatic breast cancer. Eur J Cancer 2004; 40:536-542.
7. Reichardt P, von Minckwitz G, Thuss-Patience PC, Jonat W, Kolbl H, Janicke F, et al. Multicenter phase II study of oral capecitabine (xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 2003; 14:1227-1233.
8. Zelek L, Cottu P, Tubiana-Hulin M, Vannetzel JM, Chollet P, Misset JL, et al. Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients. J Clin Oncol 2002; 20:2551-2558.
9. Razis E, Kosmidis P, Aravantinos G, Bakoyiannis C, Janinis J, Timotheadou H, et al. Second line chemotherapy with 5-fluorouracil and vinorelbine in anthracycline and taxane pretreated patients with metastatic breast cancer. Cancer Invest 2004; 22:10-15.
10. Frasci G, D'Aiuto G, Comella P, Thomas R, Capasso I, Botti G, et al. A phase I-II study on a gemcitabine-cyclophosphamide-fluorouracil/folinic acid triplet combination in anthracycline- and taxane-refractory breast cancer patients. Oncology (Huntingt) 2002; 62:25-32.
11. Vassilomanolakis M, Koumakis G, Demiri M, Missitzis J, Barbounis V, Efremidis AP. Vinorelbine and cisplatin for metastatic breast cancer: a salvage regimen in patients progressing after docetaxel and anthracycline treatment. Cancer Invest 2003; 21:497-504.
12. Margolin K, Green S, Osborne K, Doroshow JH, Akman SA, Leong LA. Phase II trial of 5-fluorouracil and high-dose folinic acid as first-or second-line therapy for advanced breast cancer. J Clin Oncol 1994; 17:175-180.
13. Chu L, Sutton J, Peterson BL, Havlin KA, Winer EP. Continuous infusion 5-fluorouracil as first-line therapy for metastatic breast cancer. J Infus Chemother 1996; 6:211-216.
14. Jabboury K, Holmes F, Hortobagyi G. 5-Fluorouracil rechallenge by protracted continuous infusion in refractory breast cancer. Cancer 1989; 64:793-797.
15. Weber B, Vogel C, Jones S, Harvey H, Hutchins L, Bigley J, et al. Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol 1995; 13:2722-2730.
16. Kornek G, Ullrich-Pur H, Penz M, Haider K, Kwasny W, Depisch D, et al. Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor. J Clin Oncol 2001; 19:621-627.
17. Berruti A, Sperone P, Bottini A, Gorzegno G, Lorusso V, Brunelli A, et al. Phase II study of vinorelbine with protracted fluorouracil infusion as a second- or third-line approach for advanced breast cancer patients previously treated with anthracyclines. J Clin Oncol 2000; 18:3370-3377.
18. Woynarowski J, Faivre S, Herzig M, Arnett B, Chapman W, Trevino AV, et al. Oxaliplatin-induced damage of cellular DNA. Mol Pharmacol 2000; 58:920-927.
19. Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, Fojo T. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen Panel. Biochem Pharmacol 1996; 52:1855-1865.
20. Raymond E, Chaney S, Taamma A, Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998; 9:1053-1071.
21. MacKay H, Cameron D, Rahilly M, Mackean M, Paul J, Kaye S, et al. Reduced MLH1 expression in breast tumors after primary chemotherapy predicts disease-free survival. J Clin Oncol 2000; 18:87-93.
22. Garufi C, Nistico C, Brienza S, Vaccaro A, D'Ottavio A, Zappala A, et al. Single-agent oxaliplatin in pretreated advanced breast cancer patients: a phase II study. Ann Oncol 2001; 12:179-182.
23. Brienza S, Gastiaburu C, Cvitkovic E, Fandi A, Hugret F, Itzhaki M, et al. Clinical characteristics and reversibility of neurological signs after long term oxaliplatin (L-OHP-transplantin) therapy. 8th NCI-EORTC symposium on new drugs in cancer therapy; 1994. p. 128.
24. Ashizawa T, Asada M, Kobayashi E, Okabe M, Gomi K, Hirata T. Combination effect of navelbine (vinorelbine ditartrate) with cisplatin against murine P388 leukemia and human lung carcinoma xenografts in mice. Anticancer Drugs 1993; 4:577-583.
25. Robieux I, Sorio R, Borsatti E, Cannizzaro R, Vitali V, Aita P, et al. Pharmacokinetics of vinorelbine in patients with liver metastases. Clin Pharmacol Ther 1996; 59:32-40.
26. Levi F, Misset JL, Brienza S, Adam R, Metzger G, Itzhaki M, et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer 1992; 69:893-900.
27. Therasse P, Arbuck SG, Eisenhauer E. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92:205-216.
28. Ravdin P. Anthracycline resistance in breast cancer: clinical applications of current knowledge. Eur J Cancer 2002; 31A:S11-S14.
29. Pivot X, Asmar L, Buzdar A, Valero V, Hortobagyi G. A unified definition of clinical anthracycline resistance breast cancer. Br J Cancer 2000; 82:529-534.
30. Piccart M, Raymond E, Aapro M, Eisenhauer EA, Cvitkovic E. Cytotoxic agents with activity in breast cancer patients previously exposed to anthracyclines: current status and future prospects. Eur J Cancer 1995; 31A:S1-S10.
31. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10:1-10.
32. Spielmann M, Martin M, Namer M, duBois A, Unger C, Dodwell DJ. Activity of pemetrexed (ALIMTA, multitargeted antifolate, LY231514) in metastatic breast cancer patients previously treated with an anthracycline and a taxane: an interim analysis. Clin Breast Cancer 2001; 2:47-51.
33. Kalbakis K, Kourousis C, Kakolyris S, Mavroudis D, Souglakos J, Agelaki S, et al. Salvage chemotherapy with high-dose leucovorin (LV) and 48-h continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes. Br J Cancer 2001; 85:798-802.
34. Delaloge S, Tubiana-Hulin M, Wardley A, Del Mastro L, Santoro A, Zambelli A, et al. A multistep randomized phase II/III trial comparing oxaliplatin (OXA) + 5fluorouracil (FU) to vinorelbine (VIN) + FU (FUN) after taxane (T)/anthracycline (A) failure in advanced/metastatic breast cancer (MBC) patients (pts): final results. Proc Am Soc Clin Oncol 2004; 23:41 (abstr 660).
35. Girre V, Dalenc F, Laurence V, Jouve M, Dieras V, Pierga JY, et al. Vinorelbine-5-fluorouracil combination as second line chemotherapy in metastatic breast cancer (MBC) after anthracycline-taxanes combination (AT). Ann Oncol 2000; 11:24 (abstr 94PD).
36. Petit T, Benider A, Yovine A, Bougnoux P, Spaeth D, Maindrault-Goebel F, et al. Phase II study of an oxaliplatin/vinorelbine combination in patients with anthracycline- and taxane-pre-treated metastatic breast cancer. Anticancer Drugs 2006; 17:337-343.
37. Wist E, Sommer H, Ostenstad B, Risberg T, Bremnes Y, Mjaaland I. Oral capecitabine in anthracycline- and taxane-pretreated advanced/ metastatic breast cancer. Acta Oncol 2004; 43:186-189.
38. Nole F, Catania C, Sanna G, Imadalou K, Munzone E, Adamoli L, et al. Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer. Ann Oncol 2006; 17:322-329.
39. Miller KD, Chap L, Holmes F, Cobleigh MA, Marcom PK, Fehrenbacher L, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23:792-799.
40. Papaldo P, Fabi A, Ferretti G, Mottolese M, Cianciulli AM, Di CB, et al. A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease. Ann Oncol 2006; 17:630-636.
41. Baweja M, Suman VJ, Fitch TR, Mailliard JA, Bernath A, Rowland KM, et al. Phase II trial of oral vinorelbine for the treatment of metastatic breast cancer in patients > or= 65 years of age: an NCCTG study. Ann Oncol 2006; 17:623-629.
42. Wyld L, Gutteridge E, Pinder SE, James JJ, Chan S, Cheung KL, et al. Prognostic factors for patients with hepatic metastases from breast cancer. Br J Cancer 2003; 89:284-290.
43. Pienkowski T, Jagiello-Gruszfeld A. Five-day infusion of fluorouracil and vinorelbine for advanced breast cancer patients treated previously with anthracyclines. Int J Clin Pharmacol Res 2001; 21:111-117.